There's new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals. US regulators are willing to reconsider using a Phase 3 study as the basis for an approval, Atara said ...

Send this story to anyone — or drop the embed into a blog post, Substack, Notion page. Every play sends rev-share back to Endpoints News.

𝕏 Post on X in Share on LinkedIn ✉ Email a friend

Heard via Storyflo

Get audio versions of every article you read.

Pick what matters — your audio curator gets you into your daily flo.

Join the listener waitlist

Atara, Pierre Fabre's cell therapy to get another shot at FDA approval · Storyflo